AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8366176
Drug: Aspirin 960
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 960 mg three times daily
Trial: 8366176
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of cyclosporine and aspirin
Trial: 26936601
Drug: Immune-enhancing dietary
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-enhancing dietary supplement for 7 days before and 5 days after surgery
Trial: 26936601
Drug: Immune-enhancing dietary
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-enhancing dietary supplement
Trial: 7787157
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg h.s.
Trial: 538766
Drug: Aspartame in
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame in solution (100 mg/kg body weight)
Trial: 538766
Drug: Aspartame in
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame in slurry (100 mg/kg body weight)
Trial: 538766
Drug: Aspartame in
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame in solution and slurry (100 mg/kg body weight)
Trial: 25993805
Drug: Compound DCR
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound DCR (1.8 g · d(‐1))
Trial: 25993805
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (75 mg · d(‐1))
Trial: 24261608
Drug: Micafungin 100
RxNorm normalized name: micafungin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 100 mg intravenously once a day for 14 days
Trial: 19696660
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of 75% fucoidan capsules for 12 days
Trial: 19696660
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of guar gum capsules for 12 days
Trial: 10475182
Drug: Tenecteplase (30-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (30-50 mg according to body weight)
Trial: 10475182
Drug: Alteplase (<=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (<= 100 mg)
Trial: 8557121
Drug: Purified FSH
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified FSH preparations
Trial: 8557121
Drug: Strategies for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategies for OHSS prevention (intravenous albumin, triggering with GnRH-a, withholding menotropin therapy)
Trial: 6175803
Drug: Alinidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 40 mg once daily
Trial: 6175803
Drug: Alinidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 40 mg twice daily
Trial: 21898040
Drug: Pentoxifylline (PTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX), 400 mg/tid from 24 h before to 24 h after coronary angioplasty
Trial: 21898040
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with routine treatment and no PTX
Trial: 18822413
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) niacin 1000 mg/day
Trial: 16255470
Drug: COX‐2 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX‐2 inhibitors (COX‐2i)
Trial: 12501222
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg twice daily plus omeprazole 20 mg daily
Trial: 2649340
Drug: Premeal injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premeal injections of short‐acting insulin and intermediate‐acting insulin at bedtime (using Novopen)
Trial: 2649340
Drug: Conventional three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional three times daily injection regimen
Trial: 334207
Drug: Anidoxime 75
RxNorm normalized name: obidoxime
DrugBank: Obidoxime (DB13750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidoxime 75 mg
Trial: 334207
Drug: Anidoxime 100
RxNorm normalized name: obidoxime
DrugBank: Obidoxime (DB13750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidoxime 100 mg
Trial: 334207
Drug: Dihydrocodeine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine 50 mg
Trial: 27136904
Drug: Ethinyl estradiol/gestodene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl estradiol/gestodene contraceptive patch
Trial: 8680050
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous corticosteroids (i.v. steroids) and conventional triple therapy
Trial: 1740541
Drug: Transdermal delivery
RxNorm normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal delivery system (TDS) with 20 mg GTN, applied for 4 successive days
Trial: 1740541
Drug: Transdermal delivery
RxNorm normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal delivery system (TDS) releasing 15 mg GTN/day
Trial: 1740541
Drug: Transdermal delivery
RxNorm normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal delivery system (TDS)
Trial: 1740541
Drug: Sublingually administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingually administered GTN
Trial: 28513525
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with soft tissue manipulation therapy
Trial: 28513525
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (triple therapy of needle, moxibustion, and cupping jar)
Trial: 19464558
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated H7N3 virus vaccine (10^7.5 TCID50 administered by nasal spray, 2 doses, 5 weeks apart)
Trial: 19464558
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated H7N3 virus vaccine (first dose)
Trial: 19464558
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated H7N3 virus vaccine (second dose)
Trial: 19464558
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated H7N3 virus vaccine
Trial: 12047396
Drug: Nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 60 mg plus metformin 1000 mg b.i.d.
Trial: 12047396
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg plus metformin 1000 mg b.i.d.
Trial: 12047396
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg plus metformin 1000 mg b.i.d. in patients with HbA1c > 9.5%.
Trial: 12047396
Drug: Nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 60 mg in patients with low HbA1c levels (<or= 8%) at baseline.
Trial: 22050786
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg b.i.d.
Trial: 12361194
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg o.d.
Trial: 11317199
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Losartan + Enalapril)
Trial: 9207352
Drug: 15% undecylenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% undecylenic acid cream
Trial: 3304029
Drug: Ketanserin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (mean dose 167 mg/day)
Trial: 18655558
Drug: Fulu Baoxinping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulu Baoxinping (FLBXP) oral liquid 10 mL thrice a day for 28 days
Trial: 18655558
Drug: Wenxin Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenxin Granule 9 g thrice a day for 28 days
Trial: 15936933
Drug: BUD/F (2x100/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/F (2x100/6 microg) administered in the evening (2000 h)
Trial: 20837588
Drug: Dexamethasone (moderately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (moderately early treatment)
Trial: 20837588
Drug: Dexamethasone (delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (delayed treatment)
Trial: 9344701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serological marker (anti-GAD) and genetic marker (HLA-DRB1)
Trial: 26773777
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) capsules at a dose of 1 g total catechin, primarily gallated type
Trial: 26773777
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) capsules
Trial: 25262522
Drug: Danhong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danhong injection 20 ml
Trial: 25262522
Drug: Blood producing
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood producing needle 400 mg (Control)
Trial: 25262522
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between experimental group and control group after treatment
Trial: 22475545
Drug: plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma exchange (as adjunctive therapy)
Trial: 20078491
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg nicotine yield cigarettes
Trial: 20078491
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg nicotine yield cigarettes
Trial: 31658113
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine lozenge
Trial: 15776771
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% cream, once daily for 12 weeks
Trial: 15776771
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% cream, once daily for 12 weeks
Trial: 12463291
Drug: Metformin (specialists)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (specialists)
Trial: 12463291
Drug: Metformin (generalists)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (generalists)
Trial: 12463291
Drug: Alpha1-blockers (specialists)
RxNorm normalized name: Thymosin alpha1 (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1-blockers (specialists)
Trial: 12463291
Drug: Alpha1-blockers (generalists)
RxNorm normalized name: Thymosin alpha1 (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1-blockers (generalists)
Trial: 8835620
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of mefloquine 1250 mg
Trial: 8835620
Drug: Divided doses
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided doses of mefloquine (750 mg and 500 mg at 6-h intervals)
Trial: 6119182
Drug: Chlorthalidone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (100 mg/day)
Trial: 6119182
Drug: Chlorthalidone +
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone + beta-blocker
Trial: 6119182
Drug: Chlorthalidone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (100 mg/day) in subgroup IA (11 men)
Trial: 6119182
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of beta-blocker in subgroup IB (5 men, 2 post-menopausal women)
Trial: 6119182
Drug: Clopamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide (5 mg/day) in group II (18 men)
Trial: 6119182
Drug: Clopamide +
RxNorm normalized name: clopamide
DrugBank: Clopamide (DB13792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopamide + pindolol (10 mg/day)
Trial: 22010913
Drug: Earlier ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Earlier ART (2 weeks after starting tuberculosis treatment)
Trial: 22010913
Drug: Later ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later ART (8 weeks after starting tuberculosis treatment)
Trial: 14674053
Drug: Nefazodone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (up to 600 mg daily)
Trial: 10965288
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy by allocation
Trial: 10965288
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy by preference
Trial: 8981691
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of betaxolol (0.25%) and pilocarpine (1.75%), used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Trial: 8981691
Drug: Betaxolol (0.25%)
DrugBank: Betaxolol (DB00195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaxolol (0.25%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Trial: 8981691
Drug: Pilocarpine (1.75%)
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine (1.75%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Trial: 8981691
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of betaxolol and pilocarpine with surfactant, used 2 times daily in Study 3.
Trial: 1289101
Drug: SK plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK plus Heparin
Trial: 3905057
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy with exercise-induced angina
Trial: 3905057
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy with exercise-induced angina
Trial: 25174776
Drug: iopromide 370
RxNorm normalized name: IOPROMIDE 370mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide 370 mgI/mL
Trial: 25174776
Drug: iopromide 300
RxNorm normalized name: IOPROMIDE 300mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide 300 mgI/mL
Trial: 22884306
Drug: Family focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family focused treatment for adolescents (FFT‐A)
Trial: 22884306
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care (a briefer psychoeducational treatment)
Trial: 15623998
Drug: Bonding agent
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bonding agent (Syntac) with amalgam
Trial: 15623998
Drug: Amalgam with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amalgam with adhesive resin luting agent (Resinomer)
Trial: 7626876
Drug: Cold blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold blood intermittent cardioplegia plus topical ice slush in hypothermic CPB
Trial: 11644558
Drug: Randomised controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised controlled trial treatment protocol
Trial: 19231043
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 200 mg
Trial: 16768834
Drug: Soya isoflavones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya isoflavones (50 mg/d)
Trial: 12963609
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid supplementation (400 mg/d)
Trial: 12086759
Drug: High-dose BEAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BEAM and transplantation of haemopoietic stem cells (BEAM‐HSCT)
Trial: 12086759
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival for both treatments
Trial: 31899499
Drug: Home exercise
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercise intervention delivered by a physical therapist with 6 home visits over 8 months and monthly calls, exercising ≥3 times weekly
Trial: 29667763
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg (open-label)
Trial: 22241704
Drug: Home-based constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based constraint-induced therapy
Trial: 20937130
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% capsaicin patch)
Trial: 20937130
Drug: 0.04% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% capsaicin control patch
Trial: 20937130
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% capsaicin patch) in patients with PHN for at least 6 months
Trial: 20937130
Drug: 0.04% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% capsaicin control patch in patients with PHN for at least 6 months
Trial: 20937130
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% capsaicin patch) at week 12 in patients with PHN for at least 6 months
Trial: 20937130
Drug: 0.04% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% capsaicin control patch at week 12 in patients with PHN for at least 6 months
Trial: 9932855
Drug: Cisapride 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 0.3 mg/kg four times a day for 8 weeks
Trial: 1969196
Drug: Local analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local analgesics (lignocaine)
Trial: 1969196
Drug: Topical analgesic
RxNorm normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesic cream (EMLA)
Trial: 7451917
Drug: Single extraamniotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single extraamniotic dose of F2-alpha prostaglandin gel
Trial: 31985294
Drug: CinnoRA® (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CinnoRA® (40 mg subcutaneous injection)
Trial: 31985294
Drug: Humira® (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humira® (40 mg subcutaneous injection)
Trial: 26036466
Drug: S-1 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 daily administration (Arm A)
Trial: 26036466
Drug: S-1 alternate-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 alternate-day administration (Arm B)
Trial: 24184429
Drug: sertraline at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline at standard dosing + CBT
Trial: 24184429
Drug: sertraline titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline titrated slowly + CBT
Trial: 24184429
Drug: pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill placebo + CBT
Trial: 8852869
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium lactate infusions
Trial: 2049259
Drug: Cifenline alone
RxNorm normalized name: cifenline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cifenline alone (160 mg)
Trial: 6363798
Drug: Indomethacin, 25
RxNorm normalized name: Indomethacin, 25 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 25 mg four times daily for 3 weeks
Trial: 31512500
Drug: Devimistat (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Devimistat (2000 mg/m2) in combination with high dose cytarabine and mitoxantrone
Trial: 31512500
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cytarabine and mitoxantrone alone
Trial: 11742907
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (4.5%) inhalation
Trial: 11742907
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (0.9%) inhalation